Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients.
Journal Information
Full Title: Therap Adv Gastroenterol
Abbreviation: Therap Adv Gastroenterol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Gastroenterology & Hepatology
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of Interest statement: Potential competing interests: Juan Córdoba (deceased) received consulting fees from Ocera Therapeutics Inc. The remaining authors declare that they have nothing to disclose.: Study medication was purchased from Ocera Therapeutics Inc., by the promoters of the study."
"Funding: This study was funded in part by the Spanish Ministry of Health, grant number, FIS 10/1028."
"The Institutional Review Boards at the study site and the Spanish Agency of Medications and Sanitary Products approved the study according to the World Medical Association’s Declaration of Helsinki. Written informed consent was obtained from subjects prior to enrolment. This study is a registered trial [ClinicalTrials.gov identifier: NCT01434108; EudraCT number: 2009-017819-16]."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025